Hipertensão arterial sistêmica como fator de risco para a forma grave da covid-19: revisão de escopo
DOI:
https://doi.org/10.11606/s1518-8787.2022056004311Palabras clave:
COVID-19, complicações, Fatores de Risco, Hipertensão, RevisãoResumen
OBJETIVO Identificar se a hipertensão arterial sistêmica se apresenta como um fator de risco para o agravamento da covid-19. MÉTODOS Trata-se de uma revisão de escopo, as buscas foram realizadas nas bases de dados Lilacs, PubMed, SciELO e Web of Science. RESULTADOS Foram selecionados 13 artigos. Os estudos apresentaram a hipertensão arterial sistêmica como a doença crônica mais comum em pacientes diagnosticados com covid-19. Os pacientes hipertensos eram mais velhos e os homens se apresentaram mais suscetíveis a desenvolver covid-19 grave. Pacientes hipertensos sem tratamento anti-hipertensivo foram associados a um maior risco de mortalidade. CONCLUSÕES Pacientes com doenças crônicas tendem a apresentar um perfil clínico diferente, sendo essencial controlar a pressão arterial em pacientes hipertensos e monitorá-los continuamente durante a infecção por covid-19.
Referencias
Pan American Health Organization. World Hypertension Day – 17 May 2021. Washington, DC: PAHO; 2021 [citado 14 jun 2021]. Disponível em: https://www.paho.org/en/events/world-hypertension-day-17-may-2021
World Health Organization. Improving hypertension control in 3 million people: country experiences of programme development and implementation. Geneva (CH): WHO; 2020 [citado 14 jun 2021]. Disponível em: https://apps.who.int/iris/handle/10665/336019
Barroso WKS, Rodrigues CIS, Bortolotto LA, Mota-Gomes MA, Brandão AA, Feitosa ADM, et al. Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol. 2021 [citado 16 jun 2021];116(3):516-658. Disponível em: http://departamentos.cardiol.br/sbc-dha/profissional/pdf/Diretriz-HAS-2020.pdf
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3
Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: ongoing controversies. Front Cardiovasc Med. 2021;8:639222. https://doi.org/10.3389/fcvm.2021.639222
Xia F, Zhang M, Cui B, An W, Chen M, Yang P, et al. COVID-19 patients with hypertension are at potential risk of worsened organ injury. Sci Rep. 2021;11:3779. https://doi.org/10.1038/s41598-021-83295-w
Garcia LB, Centurión OA. Medidas preventivas y manejo diagnóstico y terapéutico de la hipertensión arterial y las crisis hipertensivas. Rev Salud Publica Parag. 2020;10(2):59-66. https://doi.org/10.18004/rspp.2020.diciembre.59
Wei ZY, Qiao R, Chen J, Huang J, Wu H, Wang WJ, et al. The influence of pre-existing hypertension on coronavirus disease 2019 patients. Epidemiol Infect. 2021;149:e4. https://doi.org/10.1017/S0950268820003118
Yugar-Toledo JC, Yugar LBT, Tácito LHB, Vilela-Martin JF. Disfunção endotelial e hipertensão arterial. Rev Bras Hipertens. 2015 [citado 28 Jun 2021];22(3):84-92. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-881232
Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014
Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(3):745-55. https://doi.org/10.1016/j.numecd.2020.12.009
Ran J, Song Y, Zhuang Z, Han L, Zhao S, Cao P, et al. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. Hypertens Res. 2020;43(11):1267-76. https://doi.org/10.1038/s41440-020-00541-w
Chen R, Yang J, Gao X, Ding X, Yang Y, Shen Y, et al. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension. J Clin Hypertens. 2020;22(11):1974-83. https://doi.org/10.1111/jch.14038
Caldeira D, Alves M, Melo RG, António PS, Cunha N, Nunes-Ferreira A, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020;31:100627. https://doi.org/10.1016/j.ijcha.2020.100627
Fundação SEADE. Boletim Coronavírus Completo. São Paulo; 2021 [citado 21 jul 2021]. Disponível em: https://www.seade.gov.br/coronavirus/#
Zhang J, Wu J, Sun X, Xue H, Shao J, Cai W, et al. Association of hypertension with the severity and fatality of SARS-CoV-2 infection: a meta-analysis. Epidemiol Infect. 2020;148:e106. https://doi.org/10.1017/S095026882000117X
Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. Adelaide (AU): Joanna Briggs Institute; 2020 [citado 12 jun 2021]. Disponível em: https://synthesismanual.jbi.global
Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73. https://doi.org/10.7326/M18-0850
Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020;43:824-31. https://doi.org/10.1038/s41440-020-0485-2
Okay G, Durdu B, Akkoyunlu Y, Bölükçü S, Kaçmaz AB, Sümbül B, et al. Evaluation of clinical features and prognosis in COVID-19 patients with hypertension: a single-center retrospective observational study. Bezmialem Sci. 2020;8 Suppl 2:15-21. https://doi.org/10.14235/bas.galenos.2020.4978
Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39:705-16. https://doi.org/10.1038/s41587-020-00796-1
Yao Q, Ni J, Hu TT, Cai ZL, Zhao JH, Xie QW, et al. Clinical characteristics and outcomes in coronavirus disease 2019 (COVID-19) patients with and without hypertension: a retrospective study. Rev Cardiovasc Med. 2020;21(4):615-25. https://doi.org/10.31083/j.rcm.2020.04.113
Xiong TY, Huang FY, Liu Q, Peng Y, Xu YN, Wei JF, et al. Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study. Ann Med. 2020;52(7):361-6. https://doi.org/10.1080/07853890.2020.1802059
Chengyi HU, Lushan X, Hongbo Z, Yanpei Z, Wenfeng Z, Li L, et al. [Effect of hypertension on outcomes of patients with COVID-19]. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(11):1537-42. Chinese. https://doi.org/10.12122/j.issn.1673-4254.2020.11.01
Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens. 2020;42(7):656-60. https://doi.org/10.1080/10641963.2020.1764018
Yang Q, Zhou Y, Wang X, Gao S, Xiao Y, Zhang W, et al. Effect of hypertension on outcomes of adult inpatients with COVID-19 in Wuhan, China: a propensity score–matching analysis. Respir Res. 2020;21:172. https://doi.org/10.1186/s12931-020-01435-8
Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41(22):2058-66. https://doi.org/10.1093/eurheartj/ehaa433
Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5(7):825-30. https://doi.org/10.1001/jamacardio.2020.1624
Pan W, Zhang J, Wang M, Ye J, Xu Y, Shen B, et al. Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients. Hypertension. 2020;76(3):732-41. https://doi.org/10.1161/HYPERTENSIONAHA.120.15289
Rodilla E, Saura A, Jiménez I, Mendizábal A, Pineda-Cantero A, Lorenzo-Hernández E, et al. Association of hypertension with all-cause mortality among hospitalized patients with COVID-19. J Clin Med. 2020;9(10):3136. https://doi.org/10.3390/jcm9103136
Smits SL, Lang A, Brand JMA, Leijten LM, IJcken WF, Eijkemans MJC, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756. https://doi.org/10.1371/journal.ppat.1000756
Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22(11):1041-50. https://doi.org/10.1111/j.1432-2277.2009.00927.x
Devaux CA, Rolain JM, Raoult D. ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multiorgan failure, and COVID-19 disease outcome. J Microbiol Immunol Infect. 2020;53(3):425-35. https://doi.org/10.1016/j.jmii.2020.04.015
Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol. 2012;13(10):1000-9. https://doi.org/10.1038/ni.2395
Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clinic Rev Allerg Immunol. 2019;56(3):308-21. https://doi.org/10.1007/s12016-017-8648-x
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl). 2020;133(9):1087-95. https://doi.org/10.1097/CM9.0000000000000819
Mion Junior D, Silva GV, Ortega KC, Nobre F. A importância da medicação anti-hipertensiva na adesão ao tratamento. Rev Bras Hipertens. 2006 [citado 27 jun 2021];13(1):55-8. Disponível em: http://departamentos.cardiol.br/dha/revista/13-1/13-importancia-da-medicacao.pdf
Santana BS, Rodrigues BS, Stival MM, Volpe CRG. Arterial hypertension in the elderly accompanied in primary care: profile and associated factors. Esc Anna Nery. 2019;23(2):e20180322. https://doi.org/10.1590/2177-9465-EAN-2018-0322
Brandão SCS, Godoi ETAM, Ramos JOX, Melo LMMP, Sarinho ESC. Severe COVID-19: understanding the role of immunity, endothelium, and coagulation in clinical practice. J Vasc Bras. 2020;19:e20200131. https://doi.org/10.1590/1677-5449.200131
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-25. https://doi.org/10.1016/j.jinf.2020.04.021
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. https://doi.org/10.1084/jem.20200652
Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol. 2016;38(4):471-82. https://doi.org/10.1007/s00281-016-0558-0
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2022 Ana Cristina Ribeiro, Sílvia Carla da Silva André Uehara
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Cómo citar
Datos de los fondos
-
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Números de la subvención 402507/2020-7 -
Fundação de Amparo à Pesquisa do Estado de São Paulo
Números de la subvención 2019/21219-7
